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Abstract
Purpose: To establish whether first-order statistical features from [18F]fluoride and 2-deoxy-2-
[18F] fluoro-D-glucose ([18F]FDG) positron emission tomography/x-ray computed tomography
(PET/CT) demonstrate incremental value in skeletal metastasis response assessment com-
pared with maximum standardised uptake value (SUVmax).
Procedures: Sixteen patients starting endocrine treatment for de novo or progressive breast
cancer bone metastases were prospectively recruited to undergo [18F]fluoride and [18F]FDG
PET/CT scans before and 8 weeks after treatment. Percentage changes in SUV parameters,
metabolic tumour volume (MTV), total lesion metabolism (TLM), standard deviation (SD),
entropy, uniformity and absolute changes in kurtosis and skewness, from the same ≤ 5 index
lesions, were measured. Clinical response to 24 weeks, assessed by two experienced
oncologists blinded to PET/CT imaging findings, was used as a reference standard and
associations were made between parameters and progression free and overall survival.
Results: [18F]fluoride PET/CT: In four patients (20 lesions) with progressive disease (PD), TLM
and kurtosis predicted PD better than SUVmax on a patient basis (4, 4 and 3 out of 4,
respectively) and TLM, entropy, uniformity and skewness on a lesion basis (18, 16, 16, 18 and
15 out of 20, respectively). Kurtosis was independently associated with PFS (p = 0.033) and OS
(p = 0.008) on Kaplan-Meier analysis. [18F]FDG PET: No parameter provided incremental value
over SUVmax in predicting PD or non-PD. TLM was significantly associated with OS (p = 0.041)
and skewness with PFS (p = 0.005). Interlesional heterogeneity of response was seen in 11/16
and 8/16 patients on [18F]fluoride and [18F]FDG PET/CT, respectively.
Conclusion: With [18F]fluoride PET/CT, some first-order features, including those that take into
account lesion volume but also some heterogeneity parameters, provide incremental value over
SUVmax in predicting clinical response and survival in breast cancer patients with bone
metastases treated with endocrine therapy. With [18F]FDG PET/CT, no first-order parameters
Correspondence to: Gurdip Azad; e-mail: gurdip.azad@kcl.ac.uk
were more accurate than SUVmax although TLM and skewness were associated with OS and
PFS, respectively. Intra-patient heterogeneity of response occurs commonly between metasta-
ses with both tracers and most parameters.
Key words: Breast cancer, Bone metastases, Heterogeneity, [18F]fluoride PET/CT, [18F]FDG
PET/CT
Introduction
Skeletal metastases are common in patients with advanced
breast cancer and are associated with significant morbidity
[1]. With the introduction of new systemic therapies that
improve survival time, early detection and response assess-
ment of skeletal metastases has become more important.
Varied tumour response to treatment is undoubtedly an
important factor in the clinical outcome, accentuating the
need to have reliable measures to monitor patients for early
disease progression in order to allow timely discontinuation
of ineffective treatment.
Conventionally, bone scintigraphy has been used to
assess breast cancer bone metastases but has certain
limitations when assessing treatment response [2]. Molecular
and functional imaging can improve diagnosis and treatment
response assessment of breast cancer bone metastases [3].
Standardised uptake value (SUV) on positron emission
tomography/computed tomography (PET/CT) has been used
as a standard semi-quantitative method for monitoring
treatment response but other non-heterogeneity parameters
such as metabolic tumour volume (MTV) and tumour lesion
metabolism (TLM) have also been used to measure
metabolic activity within the tumour [4, 5]. Several
retrospective studies using 2-deoxy-2-[18F] fluoro-D-glucose
([18F]FDG) PET/CT, mainly focusing on osseous response
to treatment, have established that a change in SUVmax can
predict disease response or progression [6–8] and a
feasibility study has also shown that [18F]fluoride PET
may be useful in evaluating treatment response in breast
cancer [9]. Despite this, there is limited evidence to support
the use of either tracer in routine clinical practice. Measuring
volumetric parameters or heterogeneity of tracer activity has
also been shown to have incremental predictive or prognos-
tic value in a number of cancers [10–21]. First-order
statistics measure global properties of a tumour from
individual voxel values and can be obtained from the
histogram of voxel intensities and are most commonly used
[22], but there are no reports on the use of first-order
heterogeneity parameters in evaluating treatment response
assessment of breast cancer bone metastases using [18F]fluo-
ride or [18F]FDG PET.
The hypothesis of this study was that global first-order
features derived from skeletal metastases, some of which
describe heterogeneity in bone metastases, may be a better
predictor of response to treatment in comparison with
SUVmax.
The objective of this study was to extract first-order
features on both [18F]FDG (tumour-specific radiotracer that
targets glucose metabolism) and [18F]fluoride (bone-specific
tracer that targets osteoblast activity and local blood flow)
PET/CT images in breast cancer bone metastases, at baseline
and 8 weeks after endocrine treatment, and to compare their
ability to predict treatment response determined by a clinical
reference standard as well as survival with the most
commonly described parameter, SUVmax.
Materials and Methods
Participants
Sixteen female breast cancer patients (mean age 51.6, range
40–79 years) starting endocrine treatment for de novo (n = 5)
or progressive bone metastases (n = 11) from an ongoing
prospective single-centre exploratory study were included.
The endocrine treatments used were letrozole (n = 12),
tamoxifen (n = 2), everolimus/exemestane (n = 1) and anas-
trazole (n = 1). Apart from two patients who had small
volume lung and liver metastases, all other patients had
bone-only disease. [18F]fluoride and [18F]FDG PET/CT
scans were acquired before and 8 weeks after starting
treatment. The study was approved by a Research Ethics
Committee and the Administration of Radioactive Substan-
ces Advisory Committee and all patients signed an informed
consent form at the time of recruitment.
[18F]FDG PET/CT and [18F]fluoride PET/CT
Image Acquisition
After injection of [18F]FDG (mean 348 ± 18 MBq), PET/CT
scans commenced after an uptake time of 60 min. On a
separate day following injection of [18F]fluoride (mean 228
± 15 MBq), scans were performed after an uptake time of
60 min. Imaging comprised a static PET/CT scan using a GE
Discovery 710 PET/CT scanner (GE Healthcare, Chicago,
USA). Each scan covered the base of the skull to mid-thigh,
with an axial field-of-view of 15.7 cm and an 11-slice
overlap between bed positions. A low-dose CT scan
(140 kV, 10 mA, 0.5 s rotation time and 40 mm collimation)
was performed at the start of imaging to provide attenuation
correction and an anatomical reference. PET scan duration
was set to 3 min per bed position.
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PET image reconstruction included standard scanner-
based corrections for radiotracer decay, scatter, randoms and
dead-time. Emission sinograms were reconstructed with a
time-of-flight ordered subset expectation maximisation
(OSEM) algorithm (2 iterations, 24 subsets), with a 256 ×
256 matrix and a 4-mm full-width at half-maximum
(FWHM) Gaussian post-reconstruction smoothing filter on
the scanner front end, available from the manufacturer.
Parameter Analysis
Up to five of the most active (SUV ≥ 10) [23] and largest (≥
1 cm diameter) lesions were first identified for analysis on
[18F]fluoride scans in each subject. Regions of interest (ROIs)
were delineated around the same metastasis on the static
[18F]fluoride and [18F]FDG PET/CT scans by an oncologist
and radiologist working in consensus (Figs. 1 and 2). Image
heterogeneity analysis was performed using in-house quantita-
tive analysis software implemented in MATLAB (Mathworks,
Natick, MA, USA). First-order statistics derived from regional
geometry and the histogram distribution of voxel intensities
(standard deviation (SD), entropy, uniformity, kurtosis and
skewness) on both [18F]FDG and [18F]fluoride PET scans were
calculated as well as non-heterogeneity parameters such as
SUVmax, SUVmean, SUVpeak, TLM and MTV. All parameters
on both PET scans were calculated for the same lesions at
baseline and 8 weeks, and changes in the values of these
parameters from baseline were used for statistical analyses. The
tumour volumes were generally small ((mean volume =
7.1 cm3 (SD = 8.3) on [18F]fluoride PET/CT and (mean
volume = 5.7 cm3 (SD = 5.9) on [18F]FDG PET/CT)); there-
fore, in order to avoid bias from small volumes, second and
high-order texture features were not calculated [24, 25]. We
also analysed changes in SUVmax between lesions in each
individual patient to assess the degree of interlesional hetero-
geneity of response with both tracers. Interlesional heteroge-
neity was defined when a metastasis showed a change in
parameter that was opposite to the clinical reference standard.
Two experienced oncologists working in consensus,
blinded to PET/CT findings, determined clinical response
based on standard imaging including bone scans and
contrast-enhanced CT, clinical assessment, including pain
scores (using brief pain inventory questionnaire), as well as
alkaline phosphatase and carcinoma antigen 15-3 serology
up to 24 weeks after the start of treatment or until
progression, whichever came first and was used as a
reference standard (Table 1). The changes in clinical
parameters were used in patient assessment and none of
the parameters were used in isolation. Any discrepancy was
reviewed by a third clinician and only one went to a third
reader. Assessment decisions were made on bone-only
disease, given no soft tissue disease in the majority of this
group, so soft tissue response (Response Evaluation Criteria
In Solid Tumours (RECIST)) was not relevant in our studied
population. Patients were grouped into progressive disease
(PD) and non-progressive disease (non-PD = partial
response (PR) and stable disease (SD)). PR and SD patients
were assessed together as clinical management is rarely
different in these two groups.
Statistical Analysis
Statistical analysis was performed using SPSS for windows
version 24 (IBM SPSS Statistics 24). After testing for
normality, parametric or nonparametric tests were applied to
each set of data. Data that were normally distributed were
Fig. 1. Figure demonstrating regions of interest in the left humerus in a patient with clinical progressive disease. a, c [18F]FDG
and b, d [18F]fluoride PET transaxial slices a, b before and c, d 8 weeks after treatment. [18F]FDG SUVmax 14.6 at baseline and
15.4 at 8 weeks. [18F]fluoride SUVmax 37.7 at baseline, 56.5 at 8 weeks and 82.4 at 12 weeks (not shown).
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expressed as a mean and standard deviation and evaluated
using the paired t test. Data that were not normally
distributed were expressed as median and range and
evaluated using Wilcoxon signed rank test or Mann-
Whitney U test. For all statistical tests, a P value of ≤ 0.05
was considered statistically significant.
On both [18F]fluoride and [18F]FDG PET/CT scans,
optimum threshold values were established with receiver
operating characteristic analysis, maximising the sum of
sensitivity and specificity by measuring associated areas
under the ROC curves as there are no established criteria for
these tracers with endocrine treatment, although ± 25 % has
Fig. 2. Figure demonstrating regions of interest in L4 in a patient with non-progressive disease (partial response). a, c
[18F]FDG and b, d [18F]fluoride PET transaxial slices a, b before and c, d 8 weeks after treatment. [18F]FDG SUVmax 8.4 at
baseline and 4.4 at 8 weeks. [18F]fluoride SUVmax 72.1 at baseline and 46.5 at 8 weeks.
Table 1. Different parameters used in each patient for categorisation into PD or non-PD
Patient Disease
status
ALP (alkaline
phosphatase)
Ca-153 Pain score Clinical assessment Bone scan CT scan
1 PD Increased Stable Worse New bone pain Not done Increase in number of lesions
by 24 weeks
2 PD Increased Increased Stable Weight loss, vomiting Increase in number of lesions
by 24 weeks
Increase in number of lesions
by 24 weeks
3 PD Stable Increased Worse New bone pain Increase in number of lesions
by 24 weeks
Increase in number of lesions
by 24 weeks
4 PD Increased Stable Worse Worsening bone pain Increase in number of lesions
by 24 weeks
Not done
5 Non-PD Increased Increased Better Better No change No change
6 Non-PD Stable Decreased Better Stable symptoms Not done No change
7 Non-PD Stable Stable Better Asymptomatic No change No change
8 Non-PD Stable Stable Better Better No change Disappearance of some lesions
9 Non-PD Better Better Better Stable symptoms Not done Disappearance of dome lesions
10 Non-PD Better Stable Better Stable symptoms Not done No change
11 Non-PD Stable Stable Better Asymptomatic No change No change
12 Non-PD Stable Stable Better Stable symptoms No change
13 Non-PD Stable Better Stable Asymptomatic No change Disappearance of some lesions
14 Non-PD Better Better Better Stable symptoms No change Disappearance of some lesions
15 Non-PD Stable Better Better Stable symptoms Disappearance of some lesions Disappearance of some lesions
16 Non-PD Better Stable Better Stable symptoms No change No change
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been suggested for [18F]FDG post-chemotherapy [26]
(Tables 2 and 3). On this basis, we also used a 25 % cut-
off for the SUV parameters on [18F]FDG (adapted from the
EORTC criteria) and [18F]fluoride PET/CT scans, acknowl-
edging that these criteria were described for [18F]FDG PET/
CT. The values of percentage (%) changes in SUVmax,
SUVmean, SUVpeak, TLG, MTV, entropy, uniformity and
absolute changes in skewness and kurtosis, on [18F]fluoride
and [18F]FDG PET/CT scans after 8 weeks of treatment,
were calculated for all patients.
Kaplan-Meier analysis was performed using the median
value for each parameter to dichotomise the results with
differences in the curves tested with the log-rank test.
Progression free survival (PFS) was defined as the time
between the date of the start of endocrine treatment and the
date of disease progression and overall survival (OS) was
calculated from the start of endocrine treatment to the date of
death or until censoring on the date of the last follow-up.
Results
There was a total of 16 patients (72 lesions). By the clinical
reference standard, 4 patients (20 lesions) had PD at or
before 24 weeks and 12 patients (52 lesions) non-PD at
24 weeks. Patients were followed up from between 12 and
49 (median 31.5) months. Four patients died during the
follow-up period and all 16 patients progressed at between 2
and 32 (median 11.3) months.
Using the cut-offs that maximised sensitivity and speci-
ficity from ROC analysis (Tables 2 and 3), on [18F]fluoride
PET/CT, in all 16 patients, MTV, TLM, kurtosis and
skewness performed better than SUVmax on a patient basis
(10, 12, 12, 11 and 8 out of 16, respectively) and SD,
entropy, uniformity, kurtosis and skewness on a lesion basis
(53, 53, 47, 45, 55 and 44 out of 72, respectively). In the
four patients with PD, TLM and kurtosis predicted PD better
than SUVmax on a patient basis (4, 4 and 3 out of 4,
respectively) and TLM, entropy, uniformity and skewness
on a lesion basis (18, 16, 16, 18 and 15 out of 20,
respectively) (Table 2). In the 12 patients with non-PD,
[18F]fluoride MTV, TLM, SD, uniformity, kurtosis and
skewness predicted non-PD better than SUVmax on a patient
basis (10, 8, 8, 7, 8, 11 and 5 out of 12, respectively) and
MTV, SD, entropy, uniformity and skewness on a lesion
basis (44, 43, 37, 31, 37 and 30 out of 52, respectively
(Table 2). On [18F]FDG PET/CT, no parameter provided
incremental value over SUVmax overall or in predicting PD
or non-PD (Table 3).
In PD and non-PD, on both [18F]fluoride PET/CT and
[18F]FDG PET/CT scans, median % change in first-order
features was not statistically significantly different from the
median % change in the SUV parameters. On a per lesion
basis, on [18F]fluoride PET/CT, median % changes in
SUVmax, SUVmean, SUVpeak, TLM, SD and entropy were
significantly higher in PD than non-PD (− 3 vs − 20.1 %
(p = 0.021), 15.1 vs − 16 % (p = 0.001), 3 vs − 17.6 % (p = Ta
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0.003), 9.2 vs − 11.2 % (p = 0.023), 4.9 vs − 25.4 % (p =
0.022), 1.3 vs − 0.5 % (p = 0.020), respectively) and median
% changes in uniformity and kurtosis were significantly
lower in PD than non-PD (− 6.6 vs 2.9 % (p = 0.012), − 0.1
vs 0.04 % (p = 0.034), respectively) (Table 2). On [18F]FDG
PET/CT, the median % changes in SUVmax, SUVmean,
SUVpeak, MTV, TLM and SD were significantly higher in
patients with PD than non-PD (− 2.2 vs − 27.2 % (p = 0.001),
0.4 vs − 24.2 % (p = 0.001), 0.6 vs − 24.7 % (p = 0.001),
10.7 vs − 19.7 % (p = 0.006), 4.2 vs − 40.2 % (p = 0.001),
4.1 vs − 33.5 % (p = 0.004), respectively) (Table 3). Other
changes were not statistically significant.
Interlesional heterogeneity of response was seen in 11/16
and 8/16 patients on [18F]fluoride and [18F]FDG PET/CT,
respectively. For [18F]fluoride, there was a statistically
significant difference between the 15 lesions that showed
an increase in SUVmax, in patients with PD and the 22
lesions that showed an increase in SUVmax in patients with
non-PD for entropy (p = 0.028), uniformity (p = 0.008) and
kurtosis (0.033). No non-PD patient showed new lesions at
8 weeks with either [18F]FDG or [18F]fluoride PET/CT.
Kaplan-Meier analysis showed that on [18F]fluoride PET/
CT, at 8 weeks, change in kurtosis had a statistically
significant association with PFS (p = 0.033) and OS (p =
0.008) (Fig. 3a, b). On [18F]FDG PET/CT, change in TLM
was significantly associated with OS (p = 0.041) and
skewness with PFS (p = 0.005).
Discussion
Breast cancer is commonly associated with skeletal metas-
tases and early evaluation of response or progression to
treatment is vital to the optimisation of patients’ clinical
management. To our knowledge, this is the first report that
has evaluated several first-order statistical features, including
some heterogeneity parameters, for early treatment response
assessment of breast cancer bone metastases compared to
standard SUV measures using [18F]fluoride and [18F]FDG
PET/CT.
For [18F]fluoride PET/CT, several first-order global
parameters showed superiority over SUVmax, either on a
patient-based or lesion-based analysis in predicting PD,
including volume-based parameters (MTV, TLM) and
heterogeneity parameters (entropy, uniformity, kurtosis and
skewness). Additionally, kurtosis was associated with both
PFS and OS. Whilst recognition of PD is of most clinical
importance, as these patients will need an early transition to
second-line therapy, the majority of first-order parameters
were also better than SUVmax at predicting non-PD. The
observed changes in patients with PD were as expected, i.e.,
an increase in activity, volume and/or heterogeneity. In
particular, a decrease in kurtosis was also associated with
PFS and OS. This relates to an increase in spread (less
peakedness) of the voxel intensity histogram (Fig. 4a, b) or
greater Bheterogeneity^ in voxel values within lesions.Ta
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Whilst changes in SUV and volume parameters, as well
as kinetic analysis, have been reported for monitoring
therapy with [18F]fluoride PET in bone metastases [9, 27–
29], to our knowledge, there are no data describing
superiority of heterogeneity parameters in this situation.
However, first-order heterogeneity parameters have shown
predictive and prognostic ability in other cancers with
[18F]FDG PET/CT and increased heterogeneity is usually
associated with more aggressive tumours and poor treatment
response [11, 13, 21, 30].
For [18F]FDG PET/CT, no parameter performed better
than SUVmax in predicting response, although an increase in
TLM and skewness (shift of histogram to the right with
more high intensity voxels) was associated with poor OS
and PFS, respectively, whereas SUVmax was not prognostic.
In accordance with our findings, changes in SUVmax have
previously been shown to be valuable in assessing treatment
response in breast cancer skeletal metastases [7, 8].
Heterogeneity of response between metastases is a
recognised phenomenon [31] and occurred in 11/16 of our
patients with [18F]fluoride and 8/16 with [18F]FDG. The
more frequent occurrence with [18F]fluoride may be partly
explained by the flare phenomenon whereby a temporary
increase in osteoblastic activity can occur in healing
metastases in non-PD patients [32–34]. Despite this and
the fact that uptake of the two tracers is dependent on
differing underlying biological processes (tumour cell
glucose metabolism with [18F]FDG and osteoblastic miner-
alisation of bone with [18F]fluoride), both tracers offered
predictive and prognostic information at a level that would
be of clinical utility on a per patient basis. We also observed
that entropy, uniformity and kurtosis were significantly
different in the 15/20 lesions with a concordant increase in
Fig. 3. Kaplan-Meier graphs showing worse a OS and b
PFS in patients with negative changes in kurtosis less than
the median (p = 0.008 and 0.033, respectively) for [18F]fluo-
ride PET/CT scans.
Fig. 4. Voxel intensity histograms at a baseline (BL) and b
8 weeks (8W) with kernel fits of a metastasis in a patient with
PD on [18F]fluoride PET/CT. As well as an increase in
intensity of voxels (SUVmax rose from 32.7 to 38.0 and
SUVmean from 12.8–15.3), the histogram becomes less
peaked (kurtosis decreased from 5.6 to 3.1).
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SUVmax in PD patients compared to a discordant increase in
the 22/52 lesions in patients with non-PD, the latter that
could be attributed to the flare phenomenon. This would
require further prospective validation but the potential to
differentiate an increase in uptake due to true progression
from the flare phenomenon at 8 weeks would be of great
clinical utility when using [18F]fluoride PET to measure
early response, overcoming one of the limitations of bone-
specific imaging.
Limitations of this study include a relatively small
number of patients, although we were able to include a
large number of individual metastases in the analysis (n =
72). In addition, there was a smaller number of patients with
PD (n = 4) compared to non-PD which may have introduced
an element of statistical bias. Whilst all patients had similar
treatment, i.e., endocrine therapy, treatment regimens were
not exactly the same and there was probably heterogeneity in
response. Nevertheless, the main objective of this explor-
atory study was to measure response rather than treatment-
specific effects. Though our study was prospective, these
findings deserve further evaluation in larger cohorts as well
as in the assessment of different types of therapy and bone
metastases from other cancers. Whilst there is no gold
standard for determining treatment response in bone metas-
tases, our clinical reference standard was made as robust and
clinically relevant as possible by including clinical findings,
conventional imaging, biochemistry and tumour markers up
to 24 weeks assessed by two oncologists in consensus and
we were also able to include a survival analysis as an
objective assessment of the measured parameters. Whilst
criteria for response assessment have previously been
reported for [18F]FDG SUVmax or SUVpeak [3, 35], these
criteria have not been applied to other first-order parameters
and so we used optimal cut-offs in this exploratory study in
addition to 25 % cut-offs for [18F]FDG and [18F]fluoride
conventional SUV parameters. We acknowledge that repeat-
ability of first-order texture features is variable and that the
optimal cut-offs for some parameters that have been reported
as showing lower repeatability, such as uniformity and
skewness [36], may be within the limits of repeatability
measurements. Several novel parameters still performed
better, even when an optimal SUVmax cut-off was used for
comparison.
Conclusions
Our exploratory data demonstrate that certain first-order
statistical features from [18F]fluoride and [18F]FDG PET,
related to volume and heterogeneity, may provide incremen-
tal value over SUVmax in the prediction of treatment
response and survival in breast cancer bone metastases
treated with endocrine therapy, a finding that deserves
confirmation in further prospective evaluation in future
studies. In addition, with [18F]fluoride some heterogeneity
parameters can potentially differentiate an increase in
SUVmax due to flare from that due to progression of disease.
These findings may be of potential clinical utility as the
prediction of early PD helps oncologists decide whether an
earlier switch to more effective therapies is required,
whereas non-PD patients would generally continue the same
treatment if there were no significant toxicities. We also
observed that intra-patient heterogeneity of response occurs
commonly between metastases with both tracers and most
parameters.
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